Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F11%3A00050476" target="_blank" >RIV/00216224:14310/11:00050476 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209775:_____/11:#0000211 RIV/00209805:_____/11:#0000192

Výsledek na webu

<a href="http://dx.doi.org/10.3892/ijo.2011.1170" target="_blank" >http://dx.doi.org/10.3892/ijo.2011.1170</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/ijo.2011.1170" target="_blank" >10.3892/ijo.2011.1170</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

Popis výsledku v původním jazyce

We performed complex analysis of the p53 tumor suppressor in collection of 75 DLBCL cases. Fifty four patients were de novo cases, twenty one cases developed into DLBCL by transformation from less aggressive disease. We determined functional status by analysis of separated alleles in yeast (FASAY) and analyzed the p53 mutations by cDNA sequencing. We assessed the level of the p53 protein by immunoblotting analysis. We used FISH to analyze loss of the p53 and ATM (ataxia telangiectasia mutated) genes deletion. We detected 16 p53 mutations (21.3%) including the mutation activating nonsense-mediated RNA decay pathway. Deletion of the p53 allele was more common in cases with p53 mutation. Mutations and/or deletions of p53 had statistically significant negative impact on progression-free survival and tended to decrease also overall survival in 46 de novo DLBCL patients treated with R-CHOP. p53 aberrations are negative predictors for survival of DLBCL patients treated with R-CHOP.

Název v anglickém jazyce

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

Popis výsledku anglicky

We performed complex analysis of the p53 tumor suppressor in collection of 75 DLBCL cases. Fifty four patients were de novo cases, twenty one cases developed into DLBCL by transformation from less aggressive disease. We determined functional status by analysis of separated alleles in yeast (FASAY) and analyzed the p53 mutations by cDNA sequencing. We assessed the level of the p53 protein by immunoblotting analysis. We used FISH to analyze loss of the p53 and ATM (ataxia telangiectasia mutated) genes deletion. We detected 16 p53 mutations (21.3%) including the mutation activating nonsense-mediated RNA decay pathway. Deletion of the p53 allele was more common in cases with p53 mutation. Mutations and/or deletions of p53 had statistically significant negative impact on progression-free survival and tended to decrease also overall survival in 46 de novo DLBCL patients treated with R-CHOP. p53 aberrations are negative predictors for survival of DLBCL patients treated with R-CHOP.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Oncology

ISSN

1019-6439

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

1413-1420

Kód UT WoS článku

000296315400009

EID výsledku v databázi Scopus

—